--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-23-027644" form_type: "8-K" ticker: "RARE" cik: "0001515673" company_name: "Ultragenyx Pharmaceutical Inc." filed_at: "2023-06-13T23:59:59+00:00" generated_at: "2026-06-14T02:00:49.683556+00:00" event_type: "other" sentiment: "neutral" materiality_score: 0.4 calibrated_materiality_score: 0.4 confidence: "high" source: SEC EDGAR --- # Ultragenyx annual meeting approves 2023 Incentive Plan and A&R ESPP; three directors re-elected ## Summary - Stockholders elected Class I directors Emil Kakkis (58.8M for), Shehnaaz Suliman (55.7M for), Daniel Welch (52.3M for). - 2023 Incentive Plan approved: 42.0M for, 18.0M against; 5.0M broker non-votes. - A&R ESPP approved with 59.7M for, 262,515 against. - Ernst & Young ratified as independent auditor for FY2023 (63.99M for, 934,903 against). - Advisory say-on-pay passed with 56.7M for, 3.2M against. ## SEC filing metadata - accession: 0000950170-23-027644 - form_type: 8-K - ticker: RARE - cik: 0001515673 - company_name: Ultragenyx Pharmaceutical Inc. - filed_at: 2023-06-13T23:59:59+00:00 - event_type: other - sentiment: neutral - materiality_score: 0.4 - calibrated_materiality_score: 0.4 - confidence: high - sec_items: 5.02, 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/rare-20230607.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-23-027644 - JSON: https://secwatch.observer/filing/0000950170-23-027644.json - Plain text: https://secwatch.observer/filing/0000950170-23-027644.txt ## Key facts - Shareholder Votes Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the A&R ESPP at the 2023-06-07 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-06-07 source text: Proposal No. 3 – Approval of the A&R ESPP At the Annual Meeting, the Company’s stockholders approved the A&R ESPP. The votes on Proposal 3 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 59,717,345 262,515 5,566 5,026,508 evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm - Shareholder Votes Ultragenyx Pharmaceutical Inc. shareholders approved Election of Class I Directors at the 2023-06-07 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-07 source text: Proposal No. 1 – Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Emil D. Kakkis, M.D., Ph.D. 58,836,682 1,148,744 5,026,508 Shehnaaz Suliman, M.D. 55,707,622 4,277,804 5,026,508 Daniel G. Welch 52,266,359 7,719,067 5,026,508 evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm - Shareholder Votes Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the 2023 Plan at the 2023-06-07 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-06-07 source text: Proposal No. 2 – Approval of the 2023 Plan At the Annual Meeting, the Company’s stockholders approved the 2023 Plan. The votes on Proposal 2 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 41,971,776 18,008,590 5,060 5,026,508 evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm - Shareholder Votes Ultragenyx Pharmaceutical Inc. shareholders approved Advisory Vote to Approve Executive Compensation at the 2023-06-07 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-07 source text: Proposal No. 5 – Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 5 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 56,684,278 3,204,523 96,625 5,026,508 evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm - Shareholder Votes Ultragenyx Pharmaceutical Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2023-06-07 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-07 source text: Proposal No. 4 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. The votes on Proposal 4 were as follows: Votes For Votes Against Abstentions 63,986,340 934,903 90,691 evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.